Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting (July 2026)

Northwest Biotherapeutics announced that its Chief Technical Officer, Dr. Marnix Bosch, will present a scientific talk titled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses" at the 2026 British Neuro-Oncology Society (BNOS) Annual Meeting on Friday, July 3, 2026, at 10:
00 a.m. GMT.

The presentation focuses on using propensity score matching (PSM) to analyze the association between treatment with DCVax-L, an investigational personalized immune therapy for glioblastoma, and patient survival.